April 2019
Erectile dysfunction (ED) affects 50-60% of men aged 40-70, with physical trauma being a major cause, categorized as vasculogenic, neurogenic, or idiopathic.
Why this matters
Erectile dysfunction (ED) affects 50-60% of men aged 40-70, with physical trauma being a major cause, categorized as vasculogenic, neurogenic, or idiopathic. This work contributes to evidence-based plastic and reconstructive surgery — helping clinicians interpret outcomes, refine technique, and counsel patients with clearer data.
Author
Plastic and reconstructive surgery resident at Emory University (UCLA BS, USC MD) with an h-index of 21 and peer-reviewed work spanning aesthetic surgery, reconstruction, medical devices, and AI in medicine.
Abstract
Erectile dysfunction (ED) affects 50-60% of men aged 40-70, with physical trauma being a major cause, categorized as vasculogenic, neurogenic, or idiopathic. While many patients do not respond to nonsurgical treatments, few opt for surgery due to procedural complexity and low historical success rates. A review of 19 studies identified promising microsurgical treatments for ED, including microvascular arterial bypass penile revascularization surgery (MABS) and cavernous nerve graft reconstruction using end-to-side ilioinguinal, genitofemoral, and sural grafts, all showing high success rates. Additionally, minimally invasive treatments like botulinum toxin (BoNT-A) and adipose-derived stem cell (ADSC) therapy have shown potential, with BoNT-A advancing to phase II human trials. These novel microsurgical and minimally invasive approaches offer high success rates for patients with neurogenic or vasculogenic ED.